Rituximab treatment of nivolumab-induced bullous pemphigoid

JAMA Dermatology

Volumn 153, Issue 6, 2017, Pages 603-605

  Sowerby, Laura ^a   Dewan, Anna K ^a   Granter, Scott ^a   Gandhi, Leena ^b   LeBoeuf, Nicole R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BULLOUS PEMPHIGOID ANTIGEN 1; CORTICOSTEROID; DESMOGLEIN 3; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; NIVOLUMAB; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

AGED; BASEMENT MEMBRANE; BULLOUS PEMPHIGOID; CANCER REGRESSION; CASE REPORT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LETTER; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN EXAMINATION; SKIN PRURITUS; TREATMENT OUTCOME; URTICARIA; VERY ELDERLY; BIOPSY; CHEMICALLY INDUCED; DRUG EFFECT; FOLLOW UP; LUNG TUMOR; PATHOLOGY; SKIN;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOPSY; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS; MALE; NIVOLUMAB; PEMPHIGOID, BULLOUS; RITUXIMAB; SKIN;

EID: 85020727667     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2017.0091     Document Type: Letter

References (6)

1. Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688-696.
2. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383-389.
3. Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25(2):129-137.
4. Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 2015;36(7):410-418.
5. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193-3198.
6. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552-558.